Regenerex Pharma's Losses Mount, Cash Dries Up Amidst No Revenue

TL;DR

**RGPX is burning cash at an alarming rate with no revenue, making it a highly speculative bet on future capital raises that may never materialize.**

AI Summary

REGENEREX PHARMA, INC. (RGPX) reported a significant increase in net loss for the six months ended September 30, 2025, reaching $1,477,596, a substantial rise from the $802,132 net loss in the prior year period. This was primarily driven by a surge in general and administrative expenses to $1,286,987 from $512,664, and the introduction of $133,506 in research and development expenses. The company's cash and equivalents plummeted from $653,025 at March 31, 2025, to just $11,659 by September 30, 2025, indicating severe liquidity issues. Total assets decreased from $1,263,236 to $617,764, while total liabilities remained high at $5,316,564, resulting in an increased stockholders' deficit of $4,698,800. RGPX continues to operate without revenue from its acquired wound healing technologies and faces substantial doubt about its ability to continue as a going concern, with management actively seeking capital to launch its business and reduce payables.

Why It Matters

For investors, RGPX's escalating losses and near-depleted cash reserves signal extreme financial distress and a high risk of failure, especially given the lack of revenue from its core assets. Employees face job insecurity as the company struggles to secure funding and achieve profitability. Customers, particularly potential beneficiaries of its wound healing technologies, may see delays or abandonment of product development. The broader market should view RGPX as a cautionary tale of a pre-revenue company with significant operational challenges and a precarious financial position, highlighting the competitive pressures in the wound care market where established players dominate.

Risk Assessment

Risk Level: high — The company reported an accumulated deficit of $9,620,486 and excess liabilities over assets of $4,698,800 as of September 30, 2025. Cash and equivalents dropped from $653,025 to $11,659 in six months, and the company explicitly states 'These factors raise doubt about the Company's ability to continue as a going concern.'

Analyst Insight

Investors should avoid RGPX given its severe liquidity crisis, mounting losses, and explicit going concern warning. The absence of revenue from its acquired assets and reliance on future capital raises make it an extremely high-risk, speculative investment with a low probability of success.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

$617,764

total Debt

$5,316,564

net Income

-$1,477,596

eps

-$0.00

gross Margin

N/A

cash Position

$11,659

revenue Growth

N/A

Revenue Breakdown

Key Numbers

• $1,477,596 — Net Loss (Increased from $802,132 year-over-year for the six months ended September 30, 2025.)
• $11,659 — Cash and Equivalents (Dramatic decrease from $653,025 at March 31, 2025, indicating severe liquidity issues.)
• $9,620,486 — Accumulated Deficit (Increased from $8,142,891 at March 31, 2025, highlighting ongoing operational losses.)
• $4,698,800 — Total Stockholders' Deficit (Worsened from $4,156,205 at March 31, 2025, reflecting negative equity.)
• $1,286,987 — General and Administrative Expenses (More than doubled from $512,664 in the prior year period, contributing to increased losses.)
• 0 — Revenue (No revenue generated from acquired assets, despite significant operating expenses.)
• 282,372,310 — Common Shares Outstanding (As of November 17, 2025, indicating a large share count for a pre-revenue company.)
• 10,625,352 — Outstanding Warrants and Options (As of September 30, 2025, representing potential future dilution.)

Key Players & Entities

• REGENEREX PHARMA, INC. (company) — registrant
• $1,477,596 (dollar_amount) — net loss for six months ended September 30, 2025
• $802,132 (dollar_amount) — net loss for six months ended September 30, 2024
• $11,659 (dollar_amount) — cash and equivalents as of September 30, 2025
• $653,025 (dollar_amount) — cash and equivalents as of March 31, 2025
• $9,620,486 (dollar_amount) — accumulated deficit as of September 30, 2025
• $4,698,800 (dollar_amount) — total stockholders' deficit as of September 30, 2025
• Nevada (company) — state of incorporation
• SEC (regulator) — Securities and Exchange Commission
• Greenwich Resources (company) — recipient of non-cash extension fee

FAQ

Risk Factors

• Severe Liquidity Crisis [high — financial]: Cash and equivalents have plummeted from $653,025 to $11,659 in six months, indicating an inability to meet short-term obligations. Total liabilities remain high at $5,316,564 against minimal assets, leading to a substantial stockholders' deficit of $4,698,800.
• Lack of Revenue Generation [high — operational]: The company continues to operate without generating any revenue from its acquired wound healing technologies, despite incurring significant operating expenses. This lack of commercialization is a primary driver of the increasing net loss.
• Deteriorating Financial Condition [high — financial]: Net loss for the six months ended September 30, 2025, increased to $1,477,596 from $802,132 in the prior year. This is exacerbated by a more than doubling of general and administrative expenses to $1,286,987 and the introduction of R&D expenses.
• Going Concern Uncertainty [high — financial]: Management has stated substantial doubt about the company's ability to continue as a going concern. The company is actively seeking capital to launch its business and reduce payables, highlighting an immediate need for funding.
• Significant Stockholders' Deficit [high — financial]: The accumulated deficit has grown to $9,620,486, resulting in a total stockholders' deficit of $4,698,800 as of September 30, 2025. This negative equity position indicates a severe imbalance between liabilities and assets.
• Potential Dilution from Warrants and Options [medium — financial]: As of September 30, 2025, there are 10,625,352 outstanding warrants and options. These, if exercised, could lead to significant dilution for existing shareholders, especially in a pre-revenue company.
• High Operating Expenses without Revenue [high — operational]: Total operating expenses for the six months ended September 30, 2025, were $1,420,493, driven by a surge in G&A to $1,286,987 and new R&D costs of $133,506. This spending is not currently supported by any revenue.

Industry Context

The pharmaceutical industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like Regenerex Pharma are often pre-revenue for extended periods, relying on capital raises to fund operations. The competitive landscape includes established players with substantial resources and emerging biotechs, making market entry and commercialization challenging.

Regulatory Implications

As a pharmaceutical company, Regenerex Pharma is subject to stringent regulations from bodies like the FDA. Failure to meet regulatory standards for drug development, manufacturing, or marketing can lead to significant delays, fines, or product withdrawal. The company's current financial state may also impact its ability to fund necessary regulatory compliance and clinical trials.

What Investors Should Do

1. Monitor Capital Raise Efforts
2. Scrutinize Expense Management
3. Evaluate Revenue Generation Strategy
4. Assess Dilution Risk

Key Dates

• 2025-09-30: Balance Sheet Date — Reflects a severe decline in cash ($11,659) and assets ($617,764), with high liabilities ($5,316,564) and a substantial stockholders' deficit ($4,698,800).
• 2025-09-30: Statement of Operations Period End — Shows a net loss of $1,477,596 for the six months, a significant increase from the prior year, driven by soaring G&A and new R&D expenses.
• 2025-03-31: Previous Balance Sheet Date — Represents the prior financial position, showing significantly higher cash ($653,025) and total assets ($1,263,236), with a smaller stockholders' deficit ($4,156,205).

Glossary

Stockholders' Deficit

A negative equity position where total liabilities exceed total assets. (Indicates the company has more liabilities than assets, a sign of severe financial distress, as seen with RGPX's deficit of $4,698,800.)

Accumulated Deficit

The cumulative net losses of a company since its inception that have not been offset by net income or capital contributions. (Shows the extent of ongoing operational losses. RGPX's accumulated deficit increased to $9,620,486.)

Going Concern

The assumption that a company will continue to operate for the foreseeable future, typically at least 12 months. (Management's doubt about RGPX's ability to continue as a going concern highlights immediate financial viability risks.)

Anti-dilutive Securities

Securities (like options or warrants) whose potential exercise or conversion would decrease earnings per share. (RGPX excluded 10,625,352 warrants and options from EPS calculations because they were anti-dilutive, indicating their potential to significantly dilute existing shareholders.)

Capitalized Software Development

Costs incurred in developing software that are recorded as an asset on the balance sheet rather than expensed immediately. (RGPX has $38,472 in capitalized software development as of September 30, 2025, indicating investment in technology infrastructure.)

Right of Use Assets

Assets recognized under lease accounting standards, representing the right to use an underlying asset for the lease term. (RGPX has $527,235 in right-of-use assets, primarily related to leases, which are a significant component of its assets.)

Year-Over-Year Comparison

Compared to the prior year period, Regenerex Pharma has experienced a significant deterioration in its financial health. The net loss has nearly doubled to $1,477,596, primarily due to a substantial increase in general and administrative expenses and the initiation of R&D costs. Cash reserves have been depleted drastically, falling from $653,025 to $11,659, signaling severe liquidity constraints. Total assets have also decreased, while liabilities remain high, leading to a worsening stockholders' deficit. The company continues to operate without revenue, intensifying concerns about its ability to continue as a going concern.

Key Financial Figures

• $0.001 — ing at November 17, 2025 Common stock, $0.001 par value 282,372,310 "Explanatory N
• $2,400,000 — million four hundred thousand dollars ($2,400,000) note payable that was originally due A
• $10,000,000 — aised a minimum of ten million dollars ($10,000,000) in sales within twelve (12) months, or
• $500 — s are capitalized while purchases under $500 are expensed as incurred. Wound Care H

Filing Documents

• ixform10q.htm (10-Q) — 420KB
• exhibit31-1.htm (EX-31.1) — 11KB
• exhibit31-2.htm (EX-31.2) — 12KB
• exhibit32-1.htm (EX-32.1) — 5KB
• exhibit32-2.htm (EX-32.2) — 5KB
• regenerexlogo.gif (GRAPHIC) — 6KB
• 0001472375-25-000140.txt ( ) — 2506KB
• rgpx-20250930.xsd (EX-101.SCH) — 20KB
• rgpx-20250930_cal.xml (EX-101.CAL) — 33KB
• rgpx-20250930_def.xml (EX-101.DEF) — 82KB
• rgpx-20250930_lab.xml (EX-101.LAB) — 219KB
• rgpx-20250930_pre.xml (EX-101.PRE) — 181KB
• ixform10q_htm.xml (XML) — 181KB

forward-looking statements are based on a series of expectations, assumptions,

forward-looking statements are based on a series of expectations, assumptions, estimates and projections about our company, are not guarantees of future results or performance and involve substantial risks and uncertainty. We may not actually achieve the plans, intentions or expectations disclosed in these

forward-looking statements. Actual results or events could differ materially

forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking known and unknown risks and uncertainties, including the risks and uncertainties inherent in our statements regarding: our ability to add new customers; the potential benefits of and our ability to maintain our relationships, and establish or maintain future collaborations or strategic relationships or obtain additional funding; our marketing capabilities and strategy; our ability to maintain a cost-effective program; our ability to retain the continued service of our key professionals and to identify, hire and retain additional qualified professionals; our competitive position, and developments and projections relating to our competitors and our industry; our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and the impact of laws and regulations. All of our forward-looking each case, actual results may differ materially from such forward-looking information. We can give no assurance that such expectations or forward-looking change in, one or more of the risk factors or risks and uncertainties referred to in this Quarterly Report on Form 10-Q or included in our other public disclosures or our other periodic reports or other documents or filings filed with or furnished to the U.S. Securities and Exchange Commission (the "SEC") could materially and adversely affect our business, prospects, financial condition and results of operations. Except as required by law, we do not undertake or plan to update or revise any such forward-looking statements to reflect actual results, changes in plans, assumptions, estimates or project

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) 4 Balance Sheets 5 6 7 8

Notes to Financial Statements

Notes to Financial Statements 9 Item 2. Management Discussion & Analysis of Financial Condition and Results of Operations 16 Item 3

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 20 Item 4.

Controls and Procedures

Controls and Procedures 20

- OTHER INFORMATION

PART II - OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 22 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 22 Item 3. Defaults Upon Senior Securities 22 Item 4. Mining Safety Disclosures 22 Item 5 Other Information 22 Item 6. Exhibits 22 CERTIFICATIONS 31.1 Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act 31.2 Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act 32.1 Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act 32.2 Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act 4 PART I FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS REGENEREX PHARMA, INC. BALANCE SHEETS (UNAUDITED) September 30, 2025 March 31, 2025 ASSETS Current Assets Cash and equivalents $ 11,659 $ 653,025 Prepaid expenses 36,770 350 Total Current Assets 48,429 653,375 Capitalized Software Development 38,472 — Furniture and computer equipment, net of accumulated depreciation of $ 5,743 and $ 3,326 as of September 30, 2025 and March 31, 2025 3,628 5,599 Right of use assets 527,235 604,262 Total Assets $ 617,764 $ 1,263,236 LIABILITIES AND STOCKHOLDERS' DEFICIT Current Liabilities Accounts payable $ 218,748 $ 197,673 Related party advances — 13,652 Accrued compensation 808,276 842,620 Other accrued liabilities 154,357 88,268 Current portion of notes payable to shareholder 488,797 469,105 Current portion of notes payable to related parties 214,584 306,103 Current portion of notes payable 2,847,737 2,824,232 Current portion of lease liabilities 191,181 181,894 Total Current Liabilities 4,923,680 4,923,547 Lease liabilities, net of current portion 392,884 495,894 Total Liabilities 5,316,564 5,419,441 Commitments and Contingencies (Note 7) — — Stockholders' Deficit Common stock: $ 0.001 par value; 675,000,000 shares authorized; 281,750,910 and 281,070,910 issued and outstanding at September 30, 2025 and March 31, 2025 281,751 281,071 Additional paid-in capital 4,639,935 3,705,615 Accumulated deficit ( 9,620,486 ) ( 8,142,891 ) Total Stockholders' Deficit ( 4,698,800 ) ( 4,156,205 ) Total Liabilities and Stockholders' Deficit $ 617,764 $ 1,263,236 The accompanying notes are an integral part of these unaudited financial statements. 5 REGENEREX PHARMA, INC. (UNAUDITED) Three Months Ended Six Months Ended September 30, September 30, 2025 2024 2025 2024 Operating Expenses General and administrative

financial statements do not include any adjustments related to the

financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company become unable to continue as a going concern. NOTE 4 –SIGNIFICANT ACCOUNTING POLICIES Revenue Recognition The Company will record revenue under Accounting Standards Codification ("ASC") 606 by 1) identifying the contract with the customer 2) identifying the performance obligations in the contract 3) determining the transaction price, 4) allocating the transaction price to the required performance obligations in the contract, and 5) recognizing revenue when or as the companies satisfies a performance obligation. We expect to generate revenue from home care service providers that are funded by the U.S. Government, State Medicaid Programs, International Health Care Programs, Veteran's administration, Prison system, Home Health Care Providers, and other applicable Medicare reimbursement models. The Company will defer revenue where the earnings process is not yet complete. To date, no revenue has been generated from the asset acquisition disclosed in Note 1. Earnings per Share Earnings per share is reported in accordance with FASB Accounting Standards Codification ("ASC") Topic 260 " Earnings per Share " which requires dual presentation of basic earnings per share ("EPS") and diluted EPS on the face of all statements of earnings, for all entities with complex capital structures. Diluted EPS reflects the potential dilution that could occur from common shares issuable through the exercise or conversion of stock options, restricted stock awards, warrants and convertible securities. In certain circumstances, the conversion of these options, warrants and convertible securities are excluded from diluted EPS if the effect of such inclusion would be anti-dilutive. Fully diluted EPS is not provided when the effect is anti-dilutive. When the effect of dilution on loss per

financial statements. The new standard requires entities to disclose in tabular

financial statements. The new standard requires entities to disclose in tabular format certain categories of expenses, including purchases of inventory, employee compensation, depreciation, intangible asset amortization, and other specified expense categories, along with a qualitative description of amounts remaining in relevant expense captions. The objective of this ASU is to provide investors with more detailed information to better assess an entity's performance and future cash flow prospects. As clarified by ASU 2025-01 issued in January 2025, ASU 2024-03 is effective for public business entities for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of this standard on its financial statement disclosures. ASU 2025-06 - Intangibles—Goodwill and Other—Internal-Use Software In September 2025, the FASB issued ASU 2025-06, Targeted Improvements to the Accounting for Internal-Use Software , which modernizes the accounting guidance for costs associated with developing or obtaining internal-use software. The ASU eliminates the previous stage-based model (preliminary project stage, application development stage, and post-implementation stage) and replaces it with a principles-based approach that better aligns with modern software development practices, including agile and iterative methodologies. Under the new guidance, entities may begin capitalizing internal-use software development costs when (1) management has authorized and committed to funding the software project, and (2) it is probable that the project will be completed and the software will be used to perform the function intended. The ASU also supersedes the separate guidance on website development costs and incorporates it into the internal-use software framework. ASU 2025-06 is effective for all entities for annual reporting periods beginning after Decemb

View Full Filing

View this 10-Q filing on SEC EDGAR